PharmaEngine, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 06, 2023 at 05:03 pm EST
Share
PharmaEngine, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was TWD 245.94 million compared to TWD 154.88 million a year ago. Net income was TWD 80.78 million compared to TWD 87.46 million a year ago. Basic earnings per share from continuing operations was TWD 0.56 compared to TWD 0.61 a year ago. Diluted earnings per share from continuing operations was TWD 0.56 compared to TWD 0.61 a year ago.
For the nine months, sales was TWD 580.35 million compared to TWD 495.91 million a year ago. Net income was TWD 237.28 million compared to TWD 265.17 million a year ago. Basic earnings per share from continuing operations was TWD 1.65 compared to TWD 1.85 a year ago. Diluted earnings per share from continuing operations was TWD 1.65 compared to TWD 1.85 a year ago.
PharmaEngine, Inc. is a Taiwan-based company principally engaged in the development of new drugs, as well as the licensing and sales of products. The Company is developing three new anti-cancer drugs under the brand of ONIVYDE, which are nal-IRI, MM-398 and PEP02. The Company distributes its products mainly to overseas markets,